Loading clinical trials...
Loading clinical trials...
Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure (CONNECT-HF)
CONNECT-HF is a large-scale, pragmatic, cluster-randomized clinical trial to evaluate the effect of a customized, multifaceted, health system-level quality-improvement (QI) program compared with usual care on heart failure (HF) outcomes and HF quality-of-care metrics.
This trial will be a large-scale, pragmatic, cluster-randomized clinical trial to evaluate the effect of a customized, multifaceted, health system-level quality-improvement (QI) program compared with usual care on heart failure (HF) outcomes and HF quality-of-care metrics. Outcomes will be assessed following discharge for participants hospitalized with acute HF and reduced left ventricular ejection fraction. All participants in the trial will be consented for follow-up as part of the CONNECT-HF registry on clinical outcomes, medication use, and participant-centered outcomes, including quality-of-life (QOL) assessments will be collected up to 12 months post-discharge at pre-specified intervals (6 weeks and 3, 6, and 12 months). The health-system QI program will involve site visits and ongoing mentoring from teams of healthcare professionals with specialized training and field experience to help health systems and individual hospitals to design local QI plans. A key substudy will assess a participant-engagement strategy (digital) of a mobile application utilizing behavioral tools to reinforce health behaviors, including self-monitoring/self-management and medication adherence. Follow-up will occur via a centralized telephone interview by trained personnel via the DCRI Call Center. At each interview, participants will be asked to report current medications, rehospitalizations, and QOL assessments. Based on participant-reported events, medical billing data for rehospitalizations, emergency department visits, and procedures will be obtained. Quality of life assessments will include the Kansas City Cardiomyopathy Questionnaire (KCCQ) and EuroQOL five dimensions questionnaire (EQ-5D).
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
University of Alabama Hospital
Birmingham, Alabama, United States
Providence Alaska Medical Center
Anchorage, Alaska, United States
Sparks Regional Medical Center
Fort Smith, Arkansas, United States
Arkansas Heart Hospital and Clinics
Little Rock, Arkansas, United States
San Gorgonio Memorial Hospital
Banning, California, United States
Memorial Medical Center
Modesto, California, United States
Dignity Health Sequoia Hospital
Redwood City, California, United States
Riverside Community Hospital
Riverside, California, United States
Sutter Medical Center
Sacramento, California, United States
Stanford University
Stanford, California, United States
Start Date
April 21, 2017
Primary Completion Date
December 31, 2020
Completion Date
December 31, 2020
Last Updated
January 25, 2021
5,749
ACTUAL participants
Digital Engagement
OTHER
Direct Engagement
OTHER
Lead Sponsor
Duke University
Collaborators
NCT07191730
NCT07484009
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions